Novartis India Limited

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
1,055 ^INR	+0.88%		+4.37%	+36.45%

Apr. 01	Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	CI
Mar. 22	Novartis Eyes Sale of Listed Unit in India	CI

Novartis India Ltd. Announces Resignation of Girish Tekchandani as Company Secretary & Compliance Officer, Effective August 12, 2016

July 28, 2016 at 05:29 am EDT

Novartis India Ltd. announced that the board of directors of the company at its meeting held on July 28, 2016 noted and approved resignation of Mr. Girish Tekchandani as Company Secretary & Compliance Officer effective close of business hours on August 12, 2016.

Latest news about Novartis India Limited

Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	Apr. 01	CI
Novartis Eyes Sale of Listed Unit in India	Mar. 22	CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Swiss Market Index Closes in the Green on Healthcare Stocks Boost	Feb. 19	MT
Novartis Launches Strategic Review of Listed Indian Business	Feb. 19	MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India	Feb. 19	CI
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm	Feb. 17	CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18	Feb. 17	RE
Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024	Feb. 17	CI
Novartis AG Announces A Strategic Review of India Unit	Feb. 16	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024	Jan. 25	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024	Jan. 25	CI
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 25	CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-26	CI
Novartis India Limited Announces Change in Registered Office Address	23-09-15	CI
Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-26	CI
Novartis India Limited Proposes One-Time Special Dividend	23-06-30	CI
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Novartis India Limited Recommends One-Time Special Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI
Novartis India Board to Consider Interim Dividend for Fiscal 2023	23-03-06	MT
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Novartis India Limited Announces Board Changes	22-11-09	CI

Chart Novartis India Limited

Duration

Period

More charts

Company Profile

Novartis India Limited is an India-based company that is engaged in the business of trading of pharmaceuticals. The Company's portfolio of medicines addresses various therapeutic needs, such as cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India. In the bone and pain therapeutic area its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS INDIA LIMITED	+36.45%	310M
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B